

Curriculum Vitae

Simon Yannis Moritz Gräber, Dr. med.
d.o.b. August 1st, 1985, in Frankfurt am Main, Germany

University Education

2014 Doctorate Medicine, University of Heidelberg
2012 Medical Degree, University of Heidelberg
2005–2012 Studies of Medicine, University of Heidelberg

Scientific Career

Since 2025 Attending Physician at the Department of Pediatric Respiratory Medicine,
Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin
Since 2023 Principal Investigator at DZL (German Center for Lung Research)
Since 2023 Head of the junior research group “Precision Medicine in Cystic Fibrosis”
2020–2025 Subspecialty training in Pediatric Pneumology, Charité – Universitätsmedizin
Berlin
2018–2022 Clinician Scientist (BIH Program), Charité – Universitätsmedizin Berlin
2012–2018 Residency in Pediatrics, University of Heidelberg

Awards and Honors

2024 Klosterfrau Group Award for Research of Airway Diseases in Childhood
2023 Adolf-Windorfer Award (Mukoviszidose e.V.)
2020 Christiane Herzog Research Award

Citation Record

Total citations: 2,444; h-index: 29; (Web of Science, April 2026)

Top-10 selected Publications

- 1) Halle O*, **Graeber SY***, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, Koningsbruggen-Rietschel SV, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM. (*equal contribution) Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. *Eur Respir J.* 2025 Sep 18:2500150.
- 2) **Graeber SY**, Sommerburg O, Yu Y, Berges J, Hirtz S, Scheuermann H, Berger J, Duerr J, Mall MA. Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium. *Front Pharmacol.* 2025 Feb 24;16:1537095.

- 3) Loske J, Völler M, Lukassen S, Stahl M, Thürmann L, Seegebarth A, Röhmel J, Wisniewski S, Messingschlager M, Lorenz S, Klages S, Eils R, Lehmann I*, Mall MA*, **Graeber SY***, Trump S* (*equal contribution). Pharmacological Improvement of CFTR Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis. *Am J Respir Crit Care Med.* 2024 Jan 23.
- 4) Schaupp L, Addante A, Völler M, Fentker K, Bardua M, Kuppe A, Duerr J, Piehler L, Röhmel J, Thee S, Kirchner M, Ziehm M, Lauster D, Haag R, Gradzielski M, Stahl M, Mertins P*, Boutin S*, **Graeber SY***, Mall MA* (*equal contribution). Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis. *Eur Respir J.* 2023 Jul 6:2202153.
- 5) **Graeber SY**, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. *Lancet.* 2023 Sep 30;402(10408):1185-1198.
- 6) Stahl M*, Dohna M*, **Graeber SY***, Sommerburg O, Renz DM, Pallenberg ST, Voskrebenezov A, Schütz K, Hansen G, Doellinger F, Steinke E, Thee S, Röhmel J, Barth S, Rückes-Nilges C, Berges J, Hämmerling S, Wielpütz MO, Naehrlich L, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM. (*equal contribution). Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. *Eur Respir J.* 2024 Sep 5;64(3):2400004.
- 7) **Graeber SY***, Balázs A*, Ziegahn N, Rubil T, Vitzthum C, Piehler L, Drescher M, Seidel K, Rohrbach A, Röhmel J, Thee S, Duerr J, Mall MA, Stahl M (*equal contribution). Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis. *Int J Mol Sci.* 2023 Aug 2;24(15):12365.
- 8) **Graeber SY***, Renz DM*, Stahl M*, Pallenberg ST*, Sommerburg O, Naehrlich L, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Röhmel J, Allomba C, Hämmerling S, Barth S, Rückes-Nilges C, Wielpütz MO, Hansen G, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM (*equal contribution). Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med.* 2022 Aug 1;206(3):311-320.
- 9) **Graeber SY***, Vitzthum C*, Pallenberg ST*, Naehrlich L*, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tümmler B, Mall MA (*equal contribution). Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022 Mar 1;205(5):540-549.
- 10) **Graeber SY***, Dopfer C*, Naehrlich L*, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B (*equal contribution). Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis. *Am J Respir Crit Care Med.* 2018 Jun 1;197(11):1433-1442.